Please login to the form below

Not currently logged in
Email:
Password:

Kalydeco

This page shows the latest Kalydeco news and features for those working in and with pharma, biotech and healthcare.

Vertex eyes Duchenne market with Exonics, CRISPR deals

Vertex eyes Duchenne market with Exonics, CRISPR deals

Its CF drugs Kalydeco, Orkambi and Symdeko/Symkevi collectively brought in $857m in sales in the first quarter of the year, up more than a third despite payer resistance in some

Latest news

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Luckily, that plan B was waiting in the wings: Kalydeco (ivacaftor), the first ever disease-modifying treatment for cystic fibrosis gained approval in 2012. ... Jeff Leiden, Vertex CEO. The company built on its initial ‘precision medicine’ Kalydeco,

  • The Orkambi row explained The Orkambi row explained

    He says it has overpaid for Kalydeco by £400m over five years – not a ‘fair and reasonable price’. ... December 2016: NHSE approves expanded use of Kalydeco to two-to-five-year-olds in England, benefiting around 50 children.

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products. ... an overly generous deal on Vertex’s first CF drug, Kalydeco, in 2012.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... time of Kalydeco’s arrival in 2012.

  • The good, the bad and the ugly The good, the bad and the ugly

    Vertex has two - with Kalydeco sitting alongside Orkambi in an impressive respiratory portfolio.”.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    One example of this is in  cystic fibrosis, and the advent of disease modifying agents specific towards certain genetic mutations ( Kalydeco,   Orkambi).

  • Frontera Group

    2014 Rx Club of New York. Integrated Award of Excellence - Kalydeco. ... Bronze - Kalydeco - Consumer Direct Campaign. Bronze x4 - Great People Wanted (Frontera recruitment) - Business to Business Self Promotion.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics